Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 2, 1999, Pages 125-131

  Durand Zaleski, Isabelle ^a   Roche, Béatrice ^a   Buyse, Marc ^a   Carlson, Robert ^a   O'Connell, Michael ^a   Rougier, Philippe ^a   Chang, Alfred E ^a   Sondak, Vernon K ^a   Kemeny, Margaret ^a   Allen Mersh, Tim ^a   Fagniez, Pierre Louis ^a   Le Bourgeois, Jean Paul ^a   Piedbois, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DELIVERY SYSTEM; HEALTH CARE COST; HEPATIC ARTERY; HUMAN; INTERMETHOD COMPARISON; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS;

EID: 0032702228     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00043-8     Document Type: Article

References (23)

1. Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J. Natl. Cancer Inst. 88:1996;252-258.
2. Chang A.E., Schneider P.D., Sugarbaker P.H. et al. Prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann. Surg. 206:1987;685-693.
3. Hohn D.C., Stagg R.J., Friedman M.A. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J. Clin. Oncol. 7:1989;1646-1655.
4. Kemeny M.M., Goldberg D., Beatty J.D. et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal cancer. Cancer. 57:1986;492-498.
5. Kemeny N., Daly J., Reichman B. et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann. Int. Med. 107:1987;459-465.
6. Martin J.K. Jr, O'Connell M.J., Wieand H.S. et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch. Surg. 125:1990;1022-1027.
7. Rougier P., Laplanche A., Hughier M. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J. Clin. Oncol. 10:1992;1112-1118.
8. Allen-Mersh T.G., Earlam S., Fordy C. et al. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet. 344:1994;1255-1260.
9. Cole B. Evaluating the clinical and economic trade-offs of hepatic arterial infusion. J. Natl. Cancer Inst. 88:1996;223-234.
10. Economic analysis of health care technology. A report on principles. Ann. Int. Med. 122:1995;61-71.
11. Drummond M., Stoddart G., Torrance G. Methods for Economic Evaluation of Health Care Programmes. 1989;Oxford University Press, Oxford.
12. Drummond M. Cost-effectiveness guidelines for the reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics. 1:1992;85-92.
13. Taplin S., Barlow W., Urban N. et al. Stage, age, and direct costs of colon, prostate cancer and breast cancer care. J. Natl. Cancer Inst. 87:1995;417-426.
14. Findlay M. Cost analysis of palliative chemotherapy for patients with gastrointestinal malignancy. Ann. Oncol. 6:1995;205-207.
15. Smith T.J., Hillner B.E., Desch C.E. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J. Natl. Cancer Inst. 85:1993;1460-1474.
16. Hillner B., Smith T., Desch C. Efficacy and cost-effectiveness of autologous bone-marrow transplantation in metastatic breast cancer. JAMA. 267:1992;2055-2061.
17. Jonsson E. Economics in clinical cancer research: methodology and assessment. Biomed. Pharmacother. 42:1988;645-652.
18. Glimelius B., Hoffman K., Graf W. et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann. Oncol. 6:1995;267-274.
19. Laupacis A., Feeny D., Detsky A. et al. How attractive des a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 146:1992;473-481.
20. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol. 10:1992;904-911.
21. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 10:1992;896-903.
22. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by metotrexate in metastatic colorectal cancer. J. Clin. Oncol. 12:1994;960-969.
23. Efficacy of intravenous continuous infusion of flurouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:1998;301-308.